CGP-53353

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CGP-53353 (DAPH-7) 是 PKCβII 的选择性抑制剂，IC50 为 0.41 uM，对 PKCβI 表现出弱活性，IC50 为 3.8 uM。

CGP-53353 (DAPH-7) is a selective inhibitor of PKCβII with IC50 of 0.41 uM, shows weak activity on PKCβI with IC50 of 3.8 uM; also inhibits prionogenic Sup35 fibrillization (IC50= 3.4 uM) and inhibits de novo Aβ42 assembly in vitro.

CGP-53353 (DAPH-7) (1 μM; 48-96 hours) inhibits glucose-induced cell proliferation in A10 cells.CGP-53353 (1 μM ; 0-48 hours) inhibits the glucose-induced increase and acceleration of DNA synthesis in A10, also blocks the glucose-induced increase of S-phase cell percentage. Cell Proliferation AssayCell Line:A10 (cell proliferation induced by glucose) Concentration:1 μM Incubation Time:48-96 hours Result:Inhibited glucose-induced cell proliferation, although A10 cell proliferation was stimulated by increasing glucose concentrations.

——

DAPH-7

Angiogenesis

PKC

PKC

——

——

145915-60-2

365.34

C20H13F2N3O2

>98% (HPLC)

In Vitro:?DMSO : ≥ 50 mg/mL (136.86 mM)

O=C1NC(C2=C1C=C(NC3=CC=C(F)C=C3)C(NC4=CC=C(F)C=C4)=C2)=O

5,6-bis[(4-Fluorophenyl)amino]-1H-isoindole-1,3(2H)-dione

(-20℃)

With Ice Pack

≥ 2 years